Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors (ICIs) show limited efficacy in hepatocellular carcinoma (HCC) owing to an immunosuppressive tumor microenvironment (TME). Although ubiquitin-specific peptidase 39 (USP39) promotes tumor progression, its role in mediating ICI resistance remains unclear. This study aimed to elucidate how USP39 drives immunosuppression and assess its therapeutic potential in HCC. In this study, USP39 expression and prognostic relevance were analyzed using public databases and clinical samples. Functional assays were performed in vitro and in vivo. Mechanistic studies, including Co-IP/MS and GST pull-down, identified LDHA as a direct target deubiquitinated by USP39 at K318. Glycolytic activity, lactate secretion, and PD-L1 expression were assessed. A syngeneic mouse model evaluated the combined effect of USP39 knockdown and anti–PD-L1 therapy. The results indicated that USP39 was overexpressed in HCC and correlated with poor prognosis. It stabilized LDHA via deubiquitination, enhancing glycolysis and lactate production. Lactate acidified the TME, induced PD-L1 upregulation, and led to CD8⁺T cell exhaustion. USP39 depletion synergized strongly with anti–PD-L1 treatment, suppressing tumor growth and restoring T cell function. Overall, USP39 promotes ICI resistance by stabilizing LDHA to enhance glycolytic metabolism and foster an immunosuppressive TME via lactate acidosis and PD-L1 induction. Targeting USP39 may overcome ICI resistance in HCC.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: